Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and OEM. It offers electrosurgical generators based on its Helium Plasma Technology for cutting, coagulation, and ablation of soft tissue. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market that allows surgeons to operate with precision and eliminate unintended tissue trauma. It also develops, manufactures, and sells energy generators, disposable hand piece subassemblies, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
IPO Year:
Exchange: NASDAQ
Website: apyxmedical.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/17/2024 | Neutral | BTIG Research | |
| 7/14/2023 | $8.00 | Overweight | Stephens |
| 5/20/2022 | $12.00 | Buy | Lake Street |
| 8/13/2021 | $12.00 → $14.00 | Market Outperform | JMP Securities |
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4/A - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
8-K - Apyx Medical Corp (0000719135) (Filer)
10-Q - Apyx Medical Corp (0000719135) (Filer)
8-K - Apyx Medical Corp (0000719135) (Filer)
DEF 14A - Apyx Medical Corp (0000719135) (Filer)
PRE 14A - Apyx Medical Corp (0000719135) (Filer)
SD - Apyx Medical Corp (0000719135) (Filer)
8-K - Apyx Medical Corp (0000719135) (Filer)
10-Q - Apyx Medical Corp (0000719135) (Filer)
8-K - Apyx Medical Corp (0000719135) (Filer)
8-K - Apyx Medical Corp (0000719135) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
BTIG Research initiated coverage of Apyx Medical with a rating of Neutral
Stephens initiated coverage of Apyx Medical with a rating of Overweight and set a new price target of $8.00
Lake Street initiated coverage of Apyx Medical with a rating of Buy and set a new price target of $12.00
JMP Securities reiterated coverage of Apyx Medical with a rating of Market Outperform and set a new price target of $14.00 from $12.00 previously
Piper Sandler reiterated coverage of Apyx Medical with a rating of Overweight and set a new price target of $12.00 from $8.00 previously
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
4/A - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
Fastest customizable press release news feed in the world
CLEARWATER, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company") today announced that on August 4, 2025, Apyx granted a nonstatuatory stock option to purchase 100,000 shares of common stock to John Featherstone, Apyx's Vice President, North American Sales as a material inducement to such employee's employment and in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option has an exercise price of $1.85, the closing price of Apyx Medical Corporation's common stock on August 4, 2025. The stock option vests over a four-year period, with one-quarter of the shares vesting on the first anniversary of the grant date and the remain
CLEARWATER, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation, an advanced energy technology company and manufacturer of Renuvion® and the newly launched AYON Body Contouring System™, today announced the strategic appointments of two accomplished sales executives to its leadership team. These additions support the Company's continued global expansion and the commercial launch of AYON, the industry's first all-in-one surgical body contouring system. John Featherstone has been named Vice President of North American Sales, bringing more than 20 years of experience in commercial leadership roles within the aesthetics and medical device industry. Most recently serving as Vice Pr
Successfully launched AYON Body Contouring System™ to key surgeons in critical geographies; plan for commercial launch in September 2025Initiated commercial sales of Renuvion® in China with strong clinical interest and completed initial proceduresBased on pre-sales of AYON, the Company increased its total revenue guidance for FY2025 to a range of $50.0 million to $52.0 millionManagement to host a conference call today at 4:30 p.m. ET CLEARWATER, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion® and the AYON Bod
CLEARWATER, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion® and the AYON Body Contouring System™, today announced that management will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025, in Boston, MA. Charlie Goodwin, the Company's President and Chief Executive Officer, and Matt Hill, the Company's Chief Financial Officer, will participate in a fireside chat on Tuesday, August 12, 2025, at 4:00pm ET and will hold one-on-one meetings with investors throughout the day. The fir
Strong clinical interest and early procedures completed Entered into distribution agreement with GlamMoon, a division of BeauCare Clinics Investment Co., Ltd. post-initial market clearance CLEARWATER, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company") today announced the launch of Renuvion® in China as part of its international commercialization strategy. A targeted sales and marketing campaign for Renuvion is being conducted through a distribution agreement covering China with GlamMoon Medical Technology, the wholly owned equipment distribution division of BeauCare Clinics Investment Co., Ltd. ("BCC"), a leading platform compa
CLEARWATER, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion® and the AYON Body Contouring System™, today announced that financial results for the second quarter of fiscal year 2025 will be released after markets closes on Thursday, August 7th. Management will host a conference call at 4:30 p.m. Eastern Time on Thursday, August 7th, to discuss the results of the quarter, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international c
Highlighting Real Patient Journeys and Empowering Confidence Through Loose Skin Solutions and Body Contouring CLEARWATER, Fla., May 30, 2025 /PRNewswire/ -- Apyx® Medical Corporation (NASDAQ:APYX) ("Apyx Medical" or the "Company"), the manufacturer of the proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, is once again taking center stage—this time at Miami Swim Week. Following the success of its groundbreaking debut at New York Fashion Week, Renuvion will proudly feature real patients on the runway, celebrating the power of transformation and self-confidence.
The AYON Body Contouring System is the first FDA cleared all-in-one platform for the aesthetic surgical suite Plan to initiate the commercial launch of the AYON Body Contouring System to key opinion leader surgeons in critical geographies during the second half of 2025 CLEARWATER, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, is pleased to announce it has received 510(k) clearance from the U.S. Food and Drug Administration (the "FDA") for the AYON Body Contouring System™ ("AYON"). The Company is actively pr
Revenue from the Advanced Energy segment increased 6% in Q1 2025 compared with the same period last yearU.S. single use handpiece revenue grew 14% in Q1 2025 compared with the same period last yearPreparing for a planned launch of the AYON™ Body Contouring System in the second half of 2025, pending U.S. FDA clearanceManagement to host a conference call today at 8:00 a.m. ET CLEARWATER, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today reported the financial results for its first quarter ended March
Two studies report favorable clinical outcomes and safety data for Renuvion® when used during procedures that include lipoabdominoplasty for the treatment of loose and lax skin Rapid weight loss due to GLP-1 drugs expected to drive growth in patients seeking treatment for loose and lax skin CLEARWATER, Fla., April 29, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical" or the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform marketed and sold as Renuvion®, today announced the publication of two peer-reviewed clinical studies evaluating the use of Renuvion during body contouring procedures that also included lipoabdominopla
Live Leadership Updates
Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024. "On behalf of the entire organization, I would like to express our gratitude to Andrew for his lead
Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023. Mr. Hill succeeds Tara Semb, whose departure was announced by the Company on November 9, 2023. "Matt joins our executive leadership team with over 30 years of financial and operational experience, more than 20 years of which has been in the healthcare industry, where he has served as the Chief Financial Officer of four publicly-traded healthcare companies," said Charlie Goodwin, President and
NORTH BILLERICA, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("the Company") (NASDAQ:LNTH), today announced the appointment of Ms. Minnie Baylor-Henry, Esq., a renowned expert in regulatory affairs and compliance in the life sciences industry, to Lantheus' Board of Directors ("Board"), effective immediately. As an independent director, Ms. Baylor-Henry will serve as a member of the Board's Compensation Committee and the Science and Technology Committee. Following the appointment of Ms. Baylor-Henry, the Board will be comprised of nine directors, eight of whom are independent. "We are pleased to welcome Minnie Baylor-Henry, a highly respected authority in FDA law an
Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, announced today that the Company has appointed Wendy Levine to the Board of Directors, effective August 25, 2021. Ms. Levine will serve as a Director and member of the Regulatory Compliance Committee. "I am pleased to welcome Ms. Levine to our Board and look forward to leveraging her 25 years of healthcare marketing and advertising experience across the pharmaceutical, biotech, medical device and vaccine sectors," said Charlie Goodwin, Chief
This live feed shows all institutional transactions in real time.
SC 13G - Apyx Medical Corp (0000719135) (Subject)
SC 13G/A - Apyx Medical Corp (0000719135) (Subject)
SC 13D/A - Apyx Medical Corp (0000719135) (Subject)
SC 13D - Apyx Medical Corp (0000719135) (Subject)
SC 13D - Apyx Medical Corp (0000719135) (Subject)
SC 13G/A - Apyx Medical Corp (0000719135) (Subject)
SC 13G/A - Apyx Medical Corp (0000719135) (Subject)
SC 13G/A - Apyx Medical Corp (0000719135) (Subject)
SC 13G/A - Apyx Medical Corp (0000719135) (Subject)
SC 13G/A - Apyx Medical Corp (0000719135) (Subject)
Live finance-specific insights
Successfully launched AYON Body Contouring System™ to key surgeons in critical geographies; plan for commercial launch in September 2025Initiated commercial sales of Renuvion® in China with strong clinical interest and completed initial proceduresBased on pre-sales of AYON, the Company increased its total revenue guidance for FY2025 to a range of $50.0 million to $52.0 millionManagement to host a conference call today at 4:30 p.m. ET CLEARWATER, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion® and the AYON Bod
CLEARWATER, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion® and the AYON Body Contouring System™, today announced that financial results for the second quarter of fiscal year 2025 will be released after markets closes on Thursday, August 7th. Management will host a conference call at 4:30 p.m. Eastern Time on Thursday, August 7th, to discuss the results of the quarter, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international c
Revenue from the Advanced Energy segment increased 6% in Q1 2025 compared with the same period last yearU.S. single use handpiece revenue grew 14% in Q1 2025 compared with the same period last yearPreparing for a planned launch of the AYON™ Body Contouring System in the second half of 2025, pending U.S. FDA clearanceManagement to host a conference call today at 8:00 a.m. ET CLEARWATER, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today reported the financial results for its first quarter ended March
CLEARWATER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the first quarter of fiscal year 2025 will be released before markets open on Thursday, May 8th. Management will host a conference call at 8:00 a.m. Eastern Time on Thursday, May 8th to discuss the results of the quarter, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 63341. Partic
CLEARWATER, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Apyx® Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the fourth quarter and fiscal year 2024 will be released before the market opens on Thursday, March 13th. Management will host a conference call at 8:30 a.m. Eastern Time on Thursday, March 13th to discuss the results of the fourth quarter and fiscal year 2024, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 877-407-9039 (or 201-689-8470 for international call
CLEARWATER, Fla., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Apyx® Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that financial results for the third quarter of fiscal year 2024 will be released before the market opens on Friday, November 8th. Management will host a conference call at 8:00 a.m. Eastern Time on November 8th to discuss the results of the quarter, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 877-407-9039 (or 201-689-8470 for international callers) and provide access code 13
Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today reported financial results for its second quarter ended June 30, 2024; and updated its financial expectations for the full year ending December 31, 2024. Second Quarter 2024 Financial Summary: Total revenue of $12.1 million, a decrease of 10% year-over-year. Advanced Energy revenue of $9.8 million, a decrease of 17% year-over-year. OEM revenue of $2.4 million, an increase of 29% year-over-year. Net loss attributable to stockholders of $6.6 million, an increase of $5.6 million, or 5
Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that financial results for the second quarter of fiscal year 2024 will be released after the market closes on Thursday, August 8th. Management will host a conference call at 5:00 p.m. Eastern Time on August 8th to discuss the results of the quarter, and to host a question and answer session. To listen to the call by phone, interested parties may dial 888-645-4404 (or 862-298-0702 for international callers) and provide access code 13747529. Participants should ask for the Apyx Medical Corporation Call.
Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its first quarter ended March 31, 2024; and reaffirmed its financial expectations for the full year ending December 31, 2024. First Quarter 2024 Financial Summary: Total revenue of $10.2 million, a decrease of 16% year-over-year. Advanced Energy revenue of $7.5 million, a decrease of 23% year-over-year. OEM revenue of $2.8 million, an increase of 14% year-over-year. Net loss attributable to stockholders of $7.6 million, an increase of $4.1 million, or 118%, ye
Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the first quarter of fiscal year 2024 will be released before the market opens on Thursday, May 9th. Management will host a conference call at 8:00 a.m. Eastern Time on May 9th to discuss the results of the quarter, and to host a question and answer session. To listen to the call by phone, interested parties may dial 888-645-4404 (or 862-298-0702 for international callers) and provide access code 13745889. Participants should ask for the Apyx Medical Corporation Call. A live webcast